ScholarIQanswers from OpenAlex & ORCID
Hans J. Woerle
ResearcherPublications, citations & collaboration network
Hans J. Woerle is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hans J. Woerle have?
ScholarIQindexed works
Hans J. Woerle has 102 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hans J. Woerle have?
ScholarIQcitation count
Hans J. Woerle has 17,422 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hans J. Woerle?
ScholarIQh-index
Hans J. Woerle has an h-index of 54 in OpenAlex.
What is the i10-index of Hans J. Woerle?
ScholarIQi10-index
Hans J. Woerle has an i10-index of 83 in OpenAlex.
What is the ORCID of Hans J. Woerle?
ScholarIQorcid
The ORCID for Hans J. Woerle is on the source record.
What is the OpenAlex record for Hans J. Woerle?
ScholarIQopenalex
The OpenAlex for Hans J. Woerle is on the source record.
What are the most-cited papers on Hans J. Woerle?
ScholarIQmost cited works
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Bernard Zinman
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, M Maione, Vesta Lai, Alana Lee, Nora Fagan, Hans J. Woerle, Odd Erik Johansen, Uli C. Broedl, Maximilian von Eynatten
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E. Cooper, Steven E. Kahn, Nikolaus Marx, John H. Alexander, Michael Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, Hans J. Woerle, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, for the CARMELINA Investigators
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J. Woerle, Uli C. Broedl
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
Robert Ćhilton, I. Tikkanen, Christopher P. Cannon, S. Crowe, Hans J. Woerle, Uli C. Broedl, Odd Erik Johansen